Denali Therapeutics Q3 2020 Earnings Report
Key Takeaways
Denali Therapeutics reported a net loss of $58.2 million for the third quarter ended September 30, 2020. They commenced a collaboration with Biogen and completed patient enrollment in Cohort A for ETV:IDS (DNL310) Phase 1/2 in Hunter syndrome. The company's cash, cash equivalents, and marketable securities were $981.5 million as of September 30, 2020.
Commenced Biogen collaboration, receiving $560.0 million in upfront payments and potential for $1.125 billion in milestone payments plus profit sharing and royalties for the LRRK2 program.
Completed patient enrollment in Cohort A for ETV:IDS (DNL310) Phase 1/2 in Hunter syndrome, with early safety and biomarker data expected by year end 2020.
Highlighted potential of TV-enabled biotherapeutics portfolio at R&D Day, showcasing new preclinical data from ETV, PTV, ATV and OTV programs.
Entered collaboration with Secarna Pharmaceuticals to develop novel ASO therapeutics using Denali’s Oligonucleotide TV technology.